Calithera Biosciences, Inc. (CALA): Price and Financial Metrics


Calithera Biosciences, Inc. (CALA)

Today's Latest Price: $3.43 USD

0.21 (-5.77%)

Updated Sep 23 4:00pm

Add CALA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

CALA Daily Price Range
CALA 52-Week Price Range

CALA Stock Price Chart Technical Analysis Charts


CALA Price/Volume Stats

Current price $3.43 52-week high $8.18
Prev. close $3.64 52-week low $2.45
Day low $3.43 Volume 641,682
Day high $3.71 Avg. volume 684,312
50-day MA $4.31 Dividend yield N/A
200-day MA $5.43 Market Cap 242.02M

Calithera Biosciences, Inc. (CALA) Company Bio


Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company was founded in 2010 and is based in South San Francisco, California.


CALA Latest News Stream


Event/Time News Detail
Loading, please wait...

CALA Latest Social Stream


Loading social stream, please wait...

View Full CALA Social Stream

Latest CALA News From Around the Web

Below are the latest news stories about Calithera Biosciences Inc that investors may wish to consider to help them evaluate CALA as an investment opportunity.

2 “Strong Buy” Healthcare Stocks Under $5 With Massive Upside Potential

After a record-breaking August surge, volatility has made its way back to the Street. With COVID-19 continuing to impact the financial landscape and the race to the White House narrowing, the recent market volatility convey the uncertainty hanging in the balance.That’s not to say compelling plays can’t be found in the current financial environment. In particular, Wall Street analysts cite one area of the market that has been gaining steam: healthcare stocks. Additionally, the pros point out there are opportunities in this space that come with affordable price tags.It should be noted that these stocks are risky in nature, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a ...

Yahoo | September 11, 2020

Calithera to Participate in Multiple Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the company will participate in four upcoming virtual healthcare investor conferences. * Citi’s 15th Annual Biopharma Virtual Conference. Susan M. Molineaux, Ph.D., the company’s founder, president and chief executive officer, will participate in a panel presentation titled “Precision Targeted Drugs in Oncology,” on Wednesday, September 9, 2020, at 11:40 a.m. Eastern Time. * 2020 Wells Fargo Virtual Healthcare Conference. Susan M. Molineaux will participate in an analyst moderated meeti...

Yahoo | September 4, 2020

Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 8,000 shares of Calithera’s common stock, at a per share exercise price of $4.03 the closing trading price on August 31, 2020. One-fourth of the option vests in August 2021, and the balance of the option vests in a series of thirty-six successive equal monthly installments thereafter and was granted pursuant to the Calithera Biosciences, Inc. 2018 Indu...

Yahoo | September 2, 2020

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | August 18, 2020

Mixed shelf roundup - healthcare

The following companies have filed for mixed shelf offerings:Calithera Biosciences (CALA): $250M.Adaptimmune Therapeutics (ADAP): $200M.PTC Therapeutics (PTCT): Unspecified amount....

Seeking Alpha | August 11, 2020

Read More 'CALA' Stories Here

CALA Price Returns

1-mo -14.04%
3-mo -40.66%
6-mo -28.69%
1-year -3.65%
3-year -78.43%
5-year -43.12%
YTD -39.93%
2019 42.39%
2018 -51.98%
2017 156.92%
2016 -57.57%
2015 -62.08%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8082 seconds.